PTPRZ1 and neoplasm: Disrupting PTN-PTPRZ1 signaling could effectively inhibit GSC-driven tumor development, and this result meant that targeting PTN-PTPRZ1 signaling therapy could enhance treatment for GBM and other malignant tumors (Shi et al., 2017).